Gilde Healthcare leads $24 million financing round of respiratory care provider Vapotherm - Gilde Healthcare

Gilde Healthcare leads $24 million financing round of respiratory care provider Vapotherm

April 7, 2014

EXETER, New Hampshire – Vapotherm, Inc. announced a $24MM financing round led by Gilde Healthcare. Adage Capital Management joined as new co-investor. The round was completed by existing investors Morgenthaler Ventures, Kaiser Permanente, 3×5 Special Opportunity Fund, Integral Capital Partners, QuestMark Partners and Cross Creek Capital.

Geoff Pardo, Partner of Gilde Healthcare joins as new member of the Board of Directors:

“Vapotherm’s unique respiratory solution has proven to generate superior patient outcomes and lower the cost of care for providers. We look forward to grow the company internationally and improve healthcare for patients world-wide.”

Vapotherm develops, manufactures and markets advanced respiratory care devices. The company sells innovative, comfortable, noninvasive technologies for respiratory support of patients with chronic or acute breathing disorders. Over 600,000 patients have been treated with Vapotherm’s proprietary high flow therapy. For more information, visit www.vtherm.com.

 

About Gilde Healthcare (www.gildehealthcare.com)

Gilde Healthcare (Utrecht, The Netherlands and Cambridge, Massachusetts) is a transatlantic growth capital investor focused on private healthcare companies. It has over €450 million ($600 million) under management and is actively looking to lead new investments in therapeutics, diagnostics, medical devices and healthcare services. For a list of Gilde’s portfolio companies please visit our new website at www.gildehealthcare.com.

More news

Gilde Healthcare backed MedTech Group acquires precision surgical instruments and implants contract manufacturer Rudischhauser

Gilde Healthcare’s Surgical Instrument Contract Manufacturing Group (“the Group”) has acquired Rudischhauser Surgical Instruments Manufacturing GmbH (“Rudischhauser”), marking a significant milestone in the creation of a leading contract manufacturing group for precision surgical instruments. Rudischhauser...
January 26, 2026

Gilde Gilde Healthcare Portfolio company SpliceBio Initiates Dose-Expansion Portion of Phase 1/2 ASTRA Clinical Trial for SB-007 for Stargardt Disease

First dose-expansion patient successfully received SB-007  SB-007 addresses the root cause of Stargardt disease with the potential to treat patients across all ABCA4 mutations  SB-007 granted FDA Fast Track designation, following previously received Orphan Drug...
January 9, 2026

Gilde Healthcare acquires a majority stake in Physio CKI, a physiotherapy practice group, from Kapital 1852

Gilde Healthcare's private equity fund announces the acquisition of a majority stake in Physio CKI from Kapital 1852. Physio CKI is a fast-growing group of physiotherapy practices headquartered in Cologne. Founder and managing director Chaled...
December 22, 2025